Dr. Katie Murray discusses how advances in non–muscle invasive bladder cancer are shifting care toward a more collaborative, practice-wide model. She emphasizes the growing role of nurses and advanced practice providers in intravesical therapy delivery, patient education, and symptom management. As treatment expands beyond repeated TURBTs, Dr. Murray highlights the need for the entire care team to understand evolving protocols and toxicities.
Related Posts

FDA Accepts ImmunityBio sBLA for ANKTIVA Plus BCG in Papillary NMIBC
The FDA has accepted ImmunityBio’s supplemental Biologics License Application (sBLA) for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with BCG for treating patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary disease without carcinoma in situ (CIS). The agency assigned a PDUFA target action date of January 6, 2027. Clinical Takeaway The FDA’s acceptance of […]
Read More
NCCN 2026 Update Brings Risk-Adapted Stratification to Intermediate-Risk NMIBC
The 2026 NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer now incorporate the International Bladder Cancer Group (IBCG) risk stratification model for intermediate-risk non-muscle-invasive bladder cancer (NMIBC), introducing a more standardized and risk-adapted framework for patient management. The update aims to better define a historically heterogeneous disease category that has often left clinicians balancing […]
Read More